Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect on glycaemic control of liraglutide or exenatide added to metformin and/or sulphonylurea in type 2 diabetes
2006-006092-21Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Mar 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing Liraglutide add-on with Exenatide add-on (2 arms). Primary endpoint: HbA1c. Started Mar 2007; status: completed.
02
Drugs
liraglutideexenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-006092-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006092-21.